The Burden of Proof: A Four-Year Trimetazidine Ban and the Arithmetic of Tennis's Base Tier

Last Wednesday a name joined the ITIA's sanctions list. Age twenty-six. Career-high ranking 256 in doubles. Parikshit Somani, Indian. His sample contained trimetazidine — a heart medication banned at all times under Class S4 of the WADA Prohibited List. At the hearing he argued that the substance entered his body through food cooked by a family member, or through their medication. The tribunal called that defence “scientifically implausible, highly speculative and unconvincing.” The sanction is four years, running to September 2029.

In 2026, at the Sylhet Divisional Tennis Tournament, I typed that day's results at night from a paper draw sheet covering a 48-player men's draw. I became a first-night filer before I became a reporter. One thing from that habit has not changed: the scoreboard changed before the story did. This case's scoreboard carries two numbers — 256 and 2029.

There is no on-court information here. No serve percentage, no return points, no accounting of how his footwork behaves on any surface. Last year the sample was collected at a lower-tier event in Astana, Kazakhstan. Neither the event nor its tier is named; the description points to Challenger or ITF-level competition. A doubles ranking of 256 at twenty-six is what the sport calls the base tier, well below the main-tour cut. At that level players often travel alone, a coach or physio is not present at every event, and the scoreboard sits directly next to the household budget.

The ITIA is the independent body that runs tennis's anti-doping and anti-corruption programme on behalf of the ITF, ATP, WTA and the Grand Slams. A positive laboratory result is called an Adverse Analytical Finding. This case stops exactly there — one sample, one finding, one four-year term.

The real argument here is not about how good or bad he was on court; it is about who carries the burden of proof. Tennis's anti-doping system runs on strict liability: the substance in the body creates the liability, and “I did not intend it” is not a defence at the first step. Showing a plausible route is not enough; the source has to be proven. No “no fault or negligence” recognition followed. The hearing was held in August and the announcement came on Wednesday — after the normal few weeks of arbitration turnaround.

Trimetazidine is not a new name. In 2026, Kamila Valieva's case produced the same substance and the same four-year outcome. Sun Yang's 2026 case also involved the substance, but the overlap is only in the substance — the facts and procedure are a separate line. What is visible is a tribunal tone that grows steadily harder on contamination narratives. This is a trend, not an isolated ruling.

The scope of the sanction reaches past the court. During the term he cannot play, cannot coach, and cannot even attend ITF, ATP, WTA, Grand Slam or national-federation events. In other words, there is no legal way to remain inside tennis for four years.

The ranking arithmetic is simple. No points can be added or defended during the term, so the ranking will lapse entirely. Protected Ranking is generally unavailable for doping bans, because the mechanism is built for injury. If he returns in September 2029 he will be around thirty, unranked, and starting from qualifying.

The economics of the doubles base tier belong in the same sentence. For doubles players outside the top 50, covering travel, balls, strings and court fees is often a marginal fight — that is a general pattern of the tennis economy, not a specific fact of this case. The four-year term is clear in the sanctions ledger and very unclear in the household ledger. The real damage has moved from the ranking column into the career column, because the prime years now sit inside the term.

The fastest narrative to form as the case circulated was “Valieva's clone.” The similarity drawn in reporting is one of defence strategy — not factual equivalence. The player, the age, the event and the procedure all differ. Keeping that distinction intact matters, or the case gets filed in the wrong box.

Another reading spreads just as quickly: “a small player, a big punishment.” The numbers say something else. A doubles ranking of 256 at twenty-six means he was already far outside the main-tour door before the ban. The headline is large; the ranking loss is small. That gap between headline and ledger is where the case actually lives.

The defence he chose — food prepared by a family member — is the oldest and hardest route in anti-doping. The burden of proof sits on the athlete, and no household kitchen keeps a controlled record. At lower-tier events there is usually no professional nutritionist, no medication verification, no sample-planning support. Where monitoring is thin, the measure of the punishment is just as strict. That is where this case matters — the base tier, the burden of proof, and a four-year precedent on the same substance.

Two things to watch now. One is the exact start date of the term on the ITIA sanctions list; the gap between hearing date and announcement date needs reconciling. The other is whether the case goes to the Court of Arbitration for Sport. A reduction on the same ground the hearing lost is unlikely — that is the realistic arithmetic.

In my own notebook this attaches to a gap at the junior level. In December 2026 I got my first stringer's pass at the National Tennis Complex in Ramna. The night desk bought my first Ramna credential; I paid it back in deadlines. Since that year I have kept a file of names, rankings and draw positions, updated after every tournament. It has no column for food. Watching the BKSP women's squad I heard a coach explain how he moves a returner two steps inside the baseline against second serves; I never heard anyone explain how a medication name gets verified. The same gap runs through Bangladesh's pipeline, from the elite circle at Ramna to junior courts in Rajshahi, where the sponsor and television circle remains closed. I keep the beat by counting what the crowd cannot see. The numbers stay; the warnings follow.

From the inaugural generation of 2026 to the Davis Cup chapters of 2026 and 2026, this country's tennis history lives mostly on paper, in notebooks, in federation notices. A player's medication name has never entered that record. Writing “The Empty Courts” in 2026, I made 41 phone calls; the empty courts taught me how to hear a season in silence. The case that arrived from Astana into our notebooks leaves one question: is a culture of proof as easy as writing a result? In September 2029, will anyone remember that court in Astana? Probably not. The list will remain — and a list is not there to be forgotten.